Reports Q4 revenue $87.869M, consensus $86.97M. "The robust growth of CAPLYTA in 2022 marked an extraordinary year for our company. During the year we launched our new bipolar depression indication for CAPLYTA and made considerable progress in advancing our late and early-stage clinical programs," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "I am very proud of our accomplishments and the strong foundation we have built. We expect 2023 to be another year of significant growth for CAPLYTA and the company."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- FFJ short Intra-Cellular, says users reporting ‘particularly toxic side effect’
- Intra-Cellular short report concerns ‘unwarranted,’ says RBC Capital
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
- Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference